Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Sèze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A. Paul F, et al. Among authors: marignier r. Neurol Neuroimmunol Neuroinflamm. 2023 May 31;10(4):e200124. doi: 10.1212/NXI.0000000000200124. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37258412 Free PMC article.
Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
Carta S, Cobo Calvo Á, Armangué T, Saiz A, Lechner C, Rostásy K, Breu M, Baumann M, Höftberger R, Ayzenberg I, Schwake C, Sepulveda M, Martínez-Hernández E, Olivé-Cirera G, Arrambide G, Tintoré M, Bernard-Valnet R, Du Pasquier R, Brilot F, Ramanathan S, Schanda K, Gajofatto A, Ferrari S, Sechi E, Flanagan EP, Pittock SJ, Redenbaugh V, Reindl M, Marignier R, Mariotto S. Carta S, et al. Among authors: marignier r. Neurology. 2023 Mar 14;100(11):e1095-e1108. doi: 10.1212/WNL.0000000000201662. Epub 2022 Dec 16. Neurology. 2023. PMID: 36526426 Free PMC article.
Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders.
Oertel FC, Zimmermann HG, Motamedi S, Chien C, Aktas O, Albrecht P, Ringelstein M, Dcunha A, Pandit L, Martinez-Lapiscina EH, Sanchez-Dalmau B, Villoslada P, Palace J, Roca-Fernández A, Leite MI, Sharma SM, Leocani L, Pisa M, Radaelli M, Lana-Peixoto MA, Fontenelle MA, Havla J, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Marignier R, Cobo-Calvo A, Asgari N, Jacob A, Huda S, Mao-Draayer Y, Green AJ, Kenney R, Yeaman MR, Smith TJ, Cook L, Brandt AU, Paul F, Petzold A. Oertel FC, et al. Among authors: marignier r. J Neurol Neurosurg Psychiatry. 2023 Jul;94(7):560-566. doi: 10.1136/jnnp-2022-330608. Epub 2023 Feb 21. J Neurol Neurosurg Psychiatry. 2023. PMID: 36810323 Free PMC article.
Retinal Changes After Acute and Late Optic Neuritis in Aquaporin-4 Antibody Seropositive NMOSD.
Oertel FC, Zimmermann HG, Motamedi S, Bereuter C, Asseyer ES, Chien C, Marignier R, Cobo-Calvo A, Leocani L, Pisa M, Radaelli M, Villoslada P, Sanchez-Dalmau B, Martinez-Lapiscina EH, Lana-Peixoto MA, Fontenelle MA, Aktas O, Ringelstein M, Albrecht P, Green AJ, Yeaman MR, Smith TJ, Cook L, Paul F, Brandt AU. Oertel FC, et al. Among authors: marignier r. J Neuroophthalmol. 2023 Sep 29. doi: 10.1097/WNO.0000000000001991. Online ahead of print. J Neuroophthalmol. 2023. PMID: 37782525 No abstract available.
Ependyma: a new target for autoantibodies in neuromyelitis optica?
Bigotte M, Gimenez M, Gavoille A, Deligiannopoulou A, El Hajj A, Croze S, Goumaidi A, Malleret G, Salin P, Giraudon P, Ruiz A, Marignier R. Bigotte M, et al. Among authors: marignier r. Brain Commun. 2022 Nov 30;4(6):fcac307. doi: 10.1093/braincomms/fcac307. eCollection 2022. Brain Commun. 2022. PMID: 36751497 Free PMC article.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: marignier r. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. JAMA Neurol. 2024 May 1;81(5):490-498. doi: 10.1001/jamaneurol.2024.0395. JAMA Neurol. 2024. PMID: 38526462
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
Collongues N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, Ayrignac X, Bensa C, Bigaut K, Bourre B, Carra-Dallière C, Ciron J, Defer G, Kwiatkowski A, Leray E, Maillart E, Marignier R, Mathey G, Morel N, Thouvenot E, Zéphir H, Boucher J, Boutière C, Branger P, Da Silva A, Demortière S, Guillaume M, Hebant B, Januel E, Kerbrat A, Manchon E, Moisset X, Montcuquet A, Pierret C, Pique J, Poupart J, Prunis C, Roux T, Schmitt P, Androdias G, Cohen M. Collongues N, et al. Among authors: marignier r. Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880. Online ahead of print. Mult Scler. 2024. PMID: 38357870 Review.
223 results